| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 2831.0 | 2604.0 | 2585.0 |
| Other income | 155.0 | 88.0 | 86.0 |
| Total income | 2986.0 | 2692.0 | 2671.0 |
| Profit before exceptional items & tax | 963.0 | 854.0 | 864.0 |
| Exceptional items | 0.0 | 74.0 | 0.0 |
| Profit before tax | 963.0 | 780.0 | 864.0 |
| Net profit | 751.0 | 583.0 | 662.0 |
| Operating margin | 32.3% | 29.0% | 32.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +13.40% |
|---|---|
| Net profit, quarter on quarter | +28.80% |
| Revenue, year on year | +9.50% |
BSE results filing, NSE: DIVISLAB. Figures extracted from the filing.
Divi's Laboratories Ltd: key numbers
- Share price
- ₹9,619.50
- Market cap
- ₹2,55,368 Cr
- Revenue (annual)
- ₹10,560 Cr
- Net profit (annual)
- ₹2,568 Cr
- P/E (TTM)
- 87.3×Sector 50.4×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 20.19%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Divi's Laboratories Ltd
All →Divi's Laboratories Other Announcement
An immediate relative of a Divis Laboratories promoter bought equity shares worth ₹0.58 Crore through a market purchase.
- Value
- ₹0.58 Cr
Divi's Laboratories Other Announcement
Designated Person PRASAD Y.T.S. disclosed the release of two share pledges involving 2,734 equity shares. The combined transaction value of the released pledges is Rs. 2.56 Crore.
- Value
- ₹2.56 Cr
Divi's Laboratories Other Announcement
Designated person PRASAD Y.T.S. sold 6,234 equity shares of Divis Laboratories Ltd for ₹5.84 Crore via market sale.
- Value
- ₹5.84 Cr
Divi's Laboratories Promoter Selling: ₹0.19 Cr
K. Sridevi, an immediate relative, sold 200 equity shares of Divi's Laboratories Ltd via a market sale worth ₹0.19 Crore.
- Value
- ₹0.19 Cr
Divi's Laboratories Other Announcement
K. Sridevi, an immediate relative, sold 200 equity shares of Divi's Laboratories Ltd in a market transaction valued at ₹18.56 Lakh.
- Value
- ₹0.19 Cr
Divi's Laboratories Earnings Call Transcript: Key Takeaways
Divi's Laboratories showcases dominant market positioning in APIs and custom synthesis with ~$1.25B revenue, focusing on volume-led growth across 100+ countries.